Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.
Sabina Chiaretti, Alfonso Piciocchi, Cristina Skert et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia. Among 236 randomized patients, estimated 24-month event-free survival was 86% with ponatinib–blinatumomab and 67% with imatinib–chemotherapy (P<0.001). The intervention group also had higher rates of survival without measurable residual disease and complete hematologic response at the end of induction. Overall survival was 90% and 85%, respectively. The findings support the chemotherapy-free targeted and immunotherapeutic regimen as superior for the trial’s primary end point.
Key findings
- Estimated 24-month event-free survival was 86% with ponatinib–blinatumomab versus 67% with imatinib–chemotherapy (P<0.001).
- Survival with no measurable residual disease was 68% in the intervention group and 42% in the control group.
- Complete hematologic response at the end of induction occurred in 94% versus 79%, respectively.
- Overall survival was 90% with ponatinib–blinatumomab and 85% with imatinib–chemotherapy.
Why it matters
The trial provides randomized evidence that a chemotherapy-free combination of a tyrosine kinase inhibitor and immunotherapy can improve event-free survival compared with an imatinib–chemotherapy regimen in adults with Ph-positive ALL. The higher rates of measurable residual disease clearance and hematologic response also indicate stronger early disease control, while the reported overall survival difference was smaller.
What to keep in mind
Median follow-up was 23.7 months, limiting assessment of longer-term outcomes. Crossover to ponatinib–blinatumomab was allowed for control-group patients with persistent or reappearing measurable residual disease.